THE WOODLANDS, Texas,
Sept. 7, 2012 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced
today that Arthur Sands, M.D.,
Ph.D., President and Chief Executive Officer, will present at the
Morgan Stanley Global Healthcare Conference on Tuesday, September 11, at 8:00 a.m. EST in New
York City. Dr. Sands will provide an overview of Lexicon's
clinical development programs and milestones.
A webcast of the presentation will be available through
Lexicon´s website at www.lexpharma.com. An archived version of the
presentation will be available at www.lexpharma.com until
October 11, 2012.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently has
four drug programs in mid-stage development for diabetes, carcinoid
syndrome, irritable bowel syndrome and rheumatoid arthritis, all of
which were discovered by Lexicon's research team. Lexicon has used
its proprietary gene knockout technology to identify more than 100
promising drug targets. Lexicon has focused drug discovery efforts
on these biologically-validated targets to create its extensive
pipeline of clinical and preclinical programs. For additional
information about Lexicon and its programs, please visit
www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking" statements,
including statements relating to Lexicon's growth and future
operating results, discovery and development of products, strategic
alliances and intellectual property, as well as other matters that
are not historical facts or information. All forward-looking
statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important
factors, specifically including those relating to Lexicon's ability
to successfully conduct preclinical and clinical development of its
potential drug candidates, advance additional candidates into
preclinical and clinical development, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2011, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.